| Currently, the commonly used neurodevelopmental examination tools in China is applied to a wide range of ages, and the tools that can be used for neurodevelopmental screening in the neonatal period are still insufficient. To review the domestic and international clinical and scientific applications of the Hammersmith neonatal neurological examination (HNNE). Following the PRISMA guidelines, we systematically searched the Chinese and English literature on the HNNE in Web of Science, PubMed, Scopus, Embase, Cochrane Library, CNKI, and Wanfang databases, with a timeframe from the establishment of the databases to the year 2024. HNNE is a convenient, time-saving, and cost-effective neurological examination tool for predicting neurodevelopmental outcomes in newborns, showing some correlation with neuroimaging, as well as clinical significance in guiding neonatal coadministration of medications, and screening for neonatal diseases related to neurodevelopment. The HNNE can be used as a routine screening tool in the NICU and at the obstetric bedside, but a normative study of Chinese infants is needed to establish the optimal score for Chinese infants. |
